VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, January 14, 2026
Stock Comparison
AbbVie Inc. vs Eli Lilly and Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AbbVie Inc.
ABBV · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AbbVie Inc.'s moat claims, evidence, and risks.
View ABBV analysisEli Lilly and Company
LLY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.
View LLY analysisComparison highlights
- Moat score gap: Eli Lilly and Company leads (82 / 100 vs 65 / 100 for AbbVie Inc.).
- Segment focus: AbbVie Inc. has 6 segments (47.4% in Immunology); Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: AbbVie Inc. has 3 moat types across 2 domains; Eli Lilly and Company has 5 across 3.
Primary market context
AbbVie Inc.
Immunology
Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)
Global
Prescribing specialists (rheumatology, dermatology, gastroenterology), payers (PBMs/insurers), patients
Innovator biopharma (R&D, clinical development, regulated manufacturing, commercialization)
47.4%
Eli Lilly and Company
Cardiometabolic Health
Cardiometabolic pharmaceuticals (diabetes, obesity, and related metabolic diseases)
Global (with U.S. as the largest market)
Patients via prescribers and payers (commercial/government)
Branded drug developer/manufacturer
65.5%
Side-by-side metrics
Moat coverage
Shared moat types
AbbVie Inc. strengths
Eli Lilly and Company strengths
Segment mix
AbbVie Inc. segments
Full profile >Immunology
Oligopoly
Oncology
Competitive
Neuroscience
Competitive
Aesthetics
Oligopoly
Eye Care
Competitive
Other Key Products
Competitive
Eli Lilly and Company segments
Full profile >Cardiometabolic Health
Oligopoly
Oncology
Competitive
Immunology
Oligopoly
Neuroscience
Competitive
Other
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.